C07K 16/4258
Against anti-receptor ig
Official title: {against anti-receptor Ig}
C07K16/4258 (Against anti-receptor ig) appears on 183 US grants and 181 published applications in this corpus.
Search patents in C07K- Granted patents
- 183
- Published applications
- 181
- Assignees
- 114
- Inventors
- 446
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 7 | 0 |
| 1994 | 5 | 0 |
| 1995 | 5 | 0 |
| 1996 | 7 | 0 |
| 1997 | 9 | 0 |
| 1998 | 12 | 0 |
| 1999 | 14 | 0 |
| 2000 | 8 | 0 |
| 2001 | 12 | 3 |
| 2002 | 9 | 10 |
| 2003 | 3 | 14 |
| 2004 | 4 | 7 |
| 2005 | 2 | 14 |
| 2006 | 3 | 7 |
| 2007 | 4 | 9 |
| 2008 | 7 | 11 |
| 2009 | 6 | 7 |
| 2010 | 3 | 8 |
| 2011 | 5 | 5 |
| 2012 | 5 | 6 |
| 2013 | 5 | 2 |
| 2014 | 3 | 9 |
| 2015 | 3 | 7 |
| 2016 | 1 | 3 |
| 2017 | 4 | 6 |
| 2018 | 3 | 5 |
| 2019 | 1 | 0 |
| 2020 | 5 | 5 |
| 2021 | 1 | 7 |
| 2022 | 1 | 7 |
| 2023 | 2 | 5 |
| 2024 | 1 | 9 |
| 2025 | 8 | 12 |
| 2026 | 4 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Treatment of necrotizing enterocolitis with semisynthetic polyclonal human secretory immunoglobin A28 Apr 2026US 12,612,467 B2
- Recombinant cell surface capture proteins17 Mar 2026US 12,577,326 B2Regeneron Pharmaceuticals, Inc.
- FCRN/antigen-binding molecules and methods of use3 Mar 2026US 12,565,538 B2argenx BV
- Anti-BCMA car antibodies, conjugates, and methods of use10 Feb 2026US 12,545,746 B22seventy bio, Inc.
- Proteins comprising CD3 antigen binding domains and uses thereof4 Nov 2025US 12,460,001 B2Janssen Biotech, Inc.
- Anti-idiotype antibodies and uses thereof2 Jul 2026US 2026/0184818 A1Mediterranea Theranostic S.R.L.
- Fcrn/antigen-binding molecules and methods of use4 Jun 2026US 2026/0152573 A1argenx BV
- Anti-drug antibody assays5 Mar 2026US 2026/0063643 A1Amgen Inc.
- Fcrn/hsa binding molecules and methods of use18 Dec 2025US 2025/0382388 A1argenx BV
- Immunoglobulin proteins that bind to npr1 agonists30 Oct 2025US 2025/0333524 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998